Full Press Release Details
Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued Phase 3 studies in colorectal cancer, non-small cell lung cancer, and prostate cancer continue with over 70 percent enrollment completed.
REGN
Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued Phase 3 studies in colorectal cancer, non-small cell lung cancer, and prostate cancer continue with over 70 percent enrollment completed
Key Takeaway: Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued Phase 3 studies in colorectal cancer, non-small cell lung cancer, and prostate cancer continue with over 70 percent enrollment completed